CB-5083: Selective p97 Inhibition as a Precision Tool for Dissecting ER-Linked Protein and Lipid Homeostasis

Introduction

The maintenance of protein and lipid homeostasis within the endoplasmic reticulum (ER) is essential for cell survival, stress adaptation, and metabolic regulation. Aberrant ER function underlies a broad spectrum of diseases, from cancer to metabolic syndromes. A pivotal node in ER protein quality control is the AAA-ATPase p97 (also known as valosin-containing protein, VCP), a master regulator of ER-associated degradation (ERAD), unfolded protein response (UPR), and organelle homeostasis. CB-5083 (SKU: B6032), a potent, selective, and orally bioavailable p97 inhibitor, has emerged as a transformative research tool for probing these interconnected pathways. While previous articles have explored CB-5083’s role in disrupting protein homeostasis and cancer cell apoptosis (see summary here), this article uniquely integrates CB-5083’s mechanistic impact on the crosstalk between protein degradation and ER lipid metabolism, offering a deeper perspective on the analytical strategies and experimental opportunities this molecule enables.

The Central Role of p97 in Protein and Lipid Homeostasis

p97 is a ubiquitously expressed AAA-ATPase that orchestrates the extraction and delivery of poly-ubiquitinated proteins from the ER to the cytosolic proteasome for degradation. Beyond protein quality control, p97 modulates organelle biogenesis, ER membrane fusion, and trafficking of endosomal cargo. Its ATPase activity—specifically the D2 domain—fuels conformational changes critical for these processes. The link between p97 function and ER lipid metabolism has gained prominence in recent years, as studies have revealed that ER membrane expansion and lipid droplet formation are intimately tied to protein homeostasis (Carrasquillo Rodríguez et al., 2024).

Protein Quality Control and ER Stress

The ER quality control system relies on the recognition and retrotranslocation of misfolded proteins, a process heavily dependent on p97. Disruption of this pathway leads to accumulation of aberrant proteins, triggering the unfolded protein response (UPR) and, if unresolved, apoptotic cell death. The significance of UPR and p97 in cancer cell survival forms the basis for targeting this axis in oncology research.

Lipid Synthesis and Storage Regulation

Recent advances, such as the work by Carrasquillo Rodríguez et al. (2024), have revealed that the ER is not only the site of protein synthesis and folding but also the hub for de novo lipid synthesis and storage. The phosphatidic acid phosphatase lipin 1, regulated by the CTDNEP1-NEP1R1 complex, governs the balance between membrane expansion and lipid droplet formation. Notably, these regulatory mechanisms are intertwined with protein homeostasis, with p97 and the proteasome playing roles in modulating lipid enzyme stability and activity.

Mechanism of Action of CB-5083: Selective p97 AAA-ATPase Inhibition

CB-5083 is a small molecule that selectively inhibits the second ATPase domain (D2) of p97 by competitively binding the ATP site. It exhibits an impressive IC50 of 15.4 nM against wild-type p97, demonstrating both potency and specificity. The compound is orally bioavailable and has shown robust activity in preclinical models of cancer, including colorectal adenocarcinoma, non-small-cell lung cancer, and multiple myeloma.

Disruption of the Protein Degradation Pathway

By blocking p97 activity, CB-5083 prevents the clearance of poly-ubiquitinated substrates, resulting in their accumulation within the ER and cytosol. This induces severe proteotoxic stress, robust activation of the UPR, and ultimately, apoptosis via the caspase signaling pathway. In vitro, CB-5083 treatment leads to dose-dependent buildup of TCRα-GFP and poly-ubiquitinated proteins in cell lines such as HEK293T, A549, and HCT116. In vivo, oral administration of CB-5083 achieves up to 63% tumor growth inhibition in xenograft models, substantially impeding cancer progression through apoptosis induction.

Impact on Lipid Homeostasis: Insights from Recent Research

While the direct effects of CB-5083 on protein degradation are well characterized, its implications for ER lipid homeostasis are an emerging frontier. The landmark study by Carrasquillo Rodríguez et al. (2024) delineates how proteasomal degradation of regulatory subunits like NEP1R1 modulates the activity of CTDNEP1, which in turn restricts ER membrane synthesis through lipin 1 regulation. Since p97 collaborates with the proteasome in ERAD, CB-5083-mediated inhibition is poised to influence lipid synthesis indirectly by altering the turnover of lipid metabolic enzymes and their regulators. This opens new avenues for studying the interplay between protein and lipid homeostasis using CB-5083 as a molecular probe.

CB-5083 as a Platform for Advanced Experimental Strategies

Dissecting ER Crosstalk: Protein and Lipid Regulatory Networks

Traditional studies of ER-associated degradation and lipid metabolism have often been conducted in isolation. However, with tools like CB-5083, researchers can now interrogate how perturbations in protein degradation dynamically influence lipid synthesis and storage. For example, treatment of cells with CB-5083 can be combined with lipidomics profiling and quantitative proteomics to map global shifts in ER composition and function.

Modeling Cancer Cell Vulnerabilities Beyond Apoptosis

Previous reviews, such as "CB-5083: Precision Disruption of Protein Homeostasis in Cancer", have focused on apoptosis induction in cancer models. In contrast, this article highlights how CB-5083 enables the exploration of metabolic vulnerabilities in cancer cells driven by dysregulated ER lipid homeostasis. For instance, in multiple myeloma research, CB-5083 can reveal dependencies on specific lipid metabolic pathways that are masked under normal protein quality control conditions.

Methodological Innovations: Integrating CB-5083 into Multi-Omics Workflows

By leveraging CB-5083’s selective p97 AAA-ATPase inhibition, researchers can design time-course experiments to capture the kinetics of protein and lipid turnover. Coupling CB-5083 treatment with live-cell imaging, ER morphology assays, and high-resolution mass spectrometry allows for unprecedented spatial and temporal resolution of ER stress responses and metabolic remodeling.

Comparative Analysis: CB-5083 Versus Alternative Approaches

Most existing articles, such as "CB-5083: Disrupting Protein Homeostasis to Modulate ER Stress", have discussed CB-5083 in the context of general ER stress modulation. This article expands on this by providing a comparative framework:

• Genetic Knockdown/Knockout: While RNAi or CRISPR-mediated depletion of p97 can elucidate long-term effects, these approaches lack the rapid reversibility and temporal control offered by small molecule inhibitors like CB-5083.
• Other p97 Inhibitors: Compounds such as DBeQ and NMS-873 exhibit broader specificity or suboptimal pharmacokinetics. CB-5083’s oral bioavailability and selectivity make it superior for in vivo studies and translational applications.
• ER Stress Inducers: Chemical chaperones (e.g., tunicamycin, thapsigargin) induce UPR but do not specifically target the protein degradation pathway, limiting their utility in dissecting p97-specific functions.

Thus, CB-5083 represents a precision tool for uncoupling protein degradation from broader ER stress responses, uniquely enabling the study of crosstalk with lipid metabolic pathways.

Advanced Applications in Cancer and Metabolic Disease Research

Multiple Myeloma and Solid Tumor Research

CB-5083’s efficacy in preclinical xenograft models and its progression to phase 1 clinical trials underscore its relevance for both fundamental and translational research. By inducing protein homeostasis disruption and activating the UPR, CB-5083 induces cancer cell apoptosis and robust tumor growth inhibition. Notably, its ability to perturb ER homeostasis extends beyond apoptosis, potentially exposing metabolic adaptations unique to malignant cells.

Elucidating Caspase Signaling and Apoptosis Pathways

The compound’s capacity to trigger the caspase signaling pathway facilitates the dissection of apoptotic checkpoints and resistance mechanisms in cancer cells. Researchers can use CB-5083 to identify novel regulators of UPR-induced apoptosis, advancing the development of combination therapies targeting both protein degradation and metabolic vulnerabilities.

Expanding Horizons: Metabolic Disease Models

Although most studies have focused on cancer, the mechanistic overlap between ER protein and lipid homeostasis positions CB-5083 as a valuable tool for metabolic disease research. For instance, in hepatic steatosis or obesity models, CB-5083 can be used to probe how impaired protein degradation affects lipid storage, ER expansion, and systemic metabolic regulation.

Practical Considerations for Experimental Design

CB-5083 is supplied as a solid (molecular weight: 413.47, formula: C24H23N5O2) and is insoluble in water but soluble in DMSO (>20.65 mg/mL) and ethanol (>4.4 mg/mL). For optimal results, solutions should be freshly prepared, with solubility improved by warming or ultrasonic treatment. Long-term storage of solutions is discouraged; the compound should be stored at -20°C. Importantly, CB-5083 is for research use only and is not intended for diagnostic or clinical applications.

Content Hierarchy and Differentiation

While prior articles such as "CB-5083: Disrupting p97 to Unravel ER Lipid-Protein Interactions" have highlighted the intersection of protein and lipid homeostasis, this article advances the discussion by integrating recent mechanistic insights from the CTDNEP1-NEP1R1 regulatory axis and providing an explicit roadmap for multi-omics experimental design. Furthermore, unlike reviews focused solely on cancer cell apoptosis or ER stress, this piece emphasizes the analytical power of CB-5083 for dissecting protein-lipid crosstalk in both cancer and metabolic diseases.

Conclusion and Future Outlook

CB-5083 stands at the forefront of chemical biology as a selective p97 AAA-ATPase inhibitor with the unique capacity to disrupt protein homeostasis, modulate ER stress, and—through its effects on the protein degradation pathway—reveal new dimensions of lipid metabolism regulation. By leveraging recent advances in our understanding of ER regulatory networks (Carrasquillo Rodríguez et al., 2024), researchers can deploy CB-5083 to map the interplay between protein and lipid homeostasis with unprecedented precision. As new models and analytical technologies emerge, CB-5083 will remain an indispensable platform for unraveling the complexities of ER-linked disease mechanisms and identifying novel therapeutic targets.